Kanavit (Phytomenadione)

Phytomenadione serves as a cofactor for gamma‑glutamyl carboxylase, an enzyme that adds a carboxyl group to clotting factors II, VII, IX and X. This modification activates the factors, allowing the blood‑clotting cascade to proceed and correcting bleeding tendencies.

The appropriate dose of Kanavit is determined by the prescribing healthcare professional based on the patient’s clinical condition, age, weight and laboratory values. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for phytomenadione in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Kanavit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kanavit provides phytomenadione in an oral form, similar to other vitamin K1 preparations. Compared with injectable vitamin K, oral Kanavit offers convenient administration but may have slower onset of action. Choice of product depends on clinical urgency, patient preference and the treating physician’s assessment.

Kanavit should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Kanavit is taken orally, usually with water. The exact method of administration—such as with or without food—should follow the prescribing clinician’s guidance to ensure optimal absorption and effectiveness.

Serious risks include rare allergic reactions such as anaphylaxis, hemolytic anemia, and unexpected thromboembolic events. Patients should be monitored for signs of severe hypersensitivity, sudden clot formation or unexplained hemolysis, and medical attention should be sought immediately if these occur.

Kanavit should be avoided in individuals with known hypersensitivity to phytomenadione or any excipients in the formulation. Caution is also advised for patients with severe liver disease, newborns, or those receiving concurrent medications that significantly affect vitamin K metabolism.